OX003 / Oxford BioTherap - LARVOL DELTA

OBT698: a promising novel agonistic antibody for immuno-oncology and its potential as a cancer therapy for solid tumors (SITC 2023) - "OX003R expression is observed by immunohistochemistry in infiltrating lymphocytes in a variety of solid tumor types offering an alternative therapeutic option for patients who may not be suitable candidates for anti-PD1 therapy A fully humanized mAb was developed and characterized for specific binding by FACS and Retrogenix assay. Conclusions In conclusion, OBT698R is a promising immuno-oncology target with CMC ready lead therapeutic antibody. In vitro and ex vivo studies demonstrate its effectiveness and safety, showcasing its potential as an effective treatment option for cancer patients in solid tumors."

Immuno-oncology • IO biomarker • Oncology • Solid Tumor • CD40 • CD8 • GZMB

Characterization and validation of a humanized lead antibody against OX003, a novel immuno-oncology target (SITC 2022) - "release as compared to Isotype as measured by the ELISpot assay. Conclusions This data show that OX003 is a novel immunostimulatory receptor on CD8+ T cells and the lead agonistic antibody targeting OX003 enhances T cell functional activity critical for successful immunotherapy response."

IO biomarker • Oncology • Solid Tumor • CD8 • GZMB • IFNG